Scientific Sessions 2025  /  Shifting Paradigms in Lipid Management for ASCVD Risk  /  From management to cure? Assessing the promise of gene therapy for hyperlipidemia
Logo

American Heart Association

  34
  0

Final ID:

From management to cure? Assessing the promise of gene therapy for hyperlipidemia

  • Musunuru, Kiran  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
    • Author Disclosures:
    Kiran Musunuru: DO have relevant financial relationships ; Individual Stocks/Stock Options:Verve Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Beam Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Nava Therapeutics:Active (exists now) ; Advisor:Capstan Therapeutics:Active (exists now) ; Advisor:LEXEO Therapeutics:Active (exists now) ; Ownership Interest:Variant Bio:Active (exists now) ; Advisor:Verve Therapeutics:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Shifting Paradigms in Lipid Management for ASCVD Risk

Saturday, 11/08/2025 , 01:30PM - 02:45PM

Main Event

More abstracts on this topic:
Lp(a) and ASCVD: What does the causal link mean for risk reduction in practice?

O'donoghue Michelle

CORALreef Lipids Discussant

Lloyd-jones Donald

More abstracts from these authors:
Follow the white rabbit: The power of informatics to identify inherited disorders

Pepplinkhuizen Shari, Khera Amit, Musunuru Kiran

CRISPR Clarity: The Time is Now for Gene Editing in Cardiomyopathy

Musunuru Kiran, Olson Eric

You have to be authorized to contact abstract author. Please, Login
Not Available